A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Launched by ELI LILLY AND COMPANY · Apr 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called LY4086940 to see how safe it is and how the body processes it. The trial includes healthy participants as well as people who are overweight or have obesity, with or without type 2 diabetes. If you are interested in participating, you would need to meet certain criteria, such as having a steady body weight for the last three months and having a specific body mass index (BMI) based on your health status.

Participation in the trial will involve different parts. The first part will last about 10 weeks with up to six visits, while the other parts will last around 15 weeks and may include up to nine visits. During these visits, you will receive regular check-ups to monitor your health and how you respond to the medication. It's important to note that this trial is not yet recruiting participants, so if you think you might be eligible, you can keep an eye out for further announcements on how to enroll.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have no significant body weight change for the 3 months prior to screening
• Part A:
• • Are considered healthy
• • Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening
• Part B:
• • Have a BMI of 27 to 45 kg/m2 at screening
• Part C:
• • Have a BMI of 25 to 45 kg/m2 at screening
• Part D:
• • Have type 2 diabetes
• • Have hemoglobin A1C (HbA1c) ≥7.0% and ≤10.5% at screening
• • Have a BMI of 27 to 45 kg/m2 at screening
• Exclusion Criteria:
• • Have had an acute cardiovascular condition within the past 6 months prior to screening
• • Have liver disease or pancreatitis
• • Have used medications for weight loss within the 3 months prior to screening
• Parts A, B, C:
• • Have any form of diabetes
• Part D:
• • Have type 1 diabetes